Latest Breaking News On - Final distant metastasis free survival analysis - Page 1 : comparemela.com

Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.

United statesJason lukeDivision of hematology oncologyCancer immunotherapeutic centerHillman cancer centerImmunotherapy programEuropean medicines agencyNews networkCancer centerKeynote 716Keynote 9422023 asco annual meetingThe melanoma landscapeHigh riskResected melanomaFinal distant metastasis free survival analysis